MLL
IOVA icon

Moody Lynn & Lieberson’s Iovance Biotherapeutics IOVA Stock Holding History

Moody Lynn & Lieberson’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-71,735
Closed -$1.99M – 184
2019
Q4 		$1.99M Buy
71,735
+58,140
+428% +$1.32M 0.19% 92
2019
Q3 		$247K Sell
13,595
-32,350
-70% -$715K 0.03% 171
2019
Q2 		$1.13M Buy
+45,945
New +$692K 0.12% 97

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Moody Lynn & Lieberson's IOVA Position: Q1 2020 in Review

Moody Lynn & Lieberson sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 71,735 shares — an estimated $1.99M sold.

Moody Lynn & Lieberson first reported a position in IOVA in Q2 2019 and held it in 3 quarters. The position peaked at $1.99M in Q4 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • Moody Lynn & Lieberson reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 71,735 Iovance Biotherapeutics shares in Q1 2020, an estimated $1.99M.
  • Moody Lynn & Lieberson first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 3 quarters.
  • Moody Lynn & Lieberson's Iovance Biotherapeutics position peaked at $1.99M in Q4 2019.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2020, filed 30 Apr 2020.